Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Orthopedics Neurology Respiratory

CHMP recommends new use for Pierre Fabre's old beta-blocker

This article was originally published in Scrip

Executive Summary

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Pierre Fabre's Hemangiol (propranolol) in children with hemangioma, a type of birthmark. The drug is in fact a beta-blocker first developed in the 1960s, but Pierre Fabre's application of it is new, and it is now one of very few drugs approved to treat this condition.

Table

View full table

Topics

Related Companies

Tags:
Orthopedics Neurology Respiratory
Latest Headlines

AbbVie Claims Rinvoq Superiority To Dupixent In AD

Merck Investors Keeping A Close Watch On Winrevair Uptake

‘It’s Not About Me’ – AstraZeneca’s Soriot Says His Pay Rise Will Help European Pharma

Executives On The Move: Three New CEOs Among This Week's Changes

See All
UsernamePublicRestriction

Register

SC024515

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By